MedTrace Logo

Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity

NCT02902913 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-04-27

Study results available
· View outcomes & findings →

Summary

Data from limited dietary intervention trials suggest that the cardiovascular health benefit of extra virgin olive oil (EVOO) may increase with phenolic content. However, while EVOOs contain an array of bioactive compounds, little information exists regarding the physiological effects of specific chemical species. Among the EVOO-derived phenolics with demonstrated anti-inflammatory effects in animal and in vitro models is oleocanthal, an inhibitor of cyclooxygenase (COX). The current study compared the impact of acute intake (40 mL) of EVOO on platelet reactivity in healthy adult males (n=9). The volunteers were randomly assigned to consume three EVOOs in a double-blind controlled trial. The EVOO were characterized and chosen for equivalency in their total phenolic content and fatty acid profiles, but differing in their oleocanthal to oleacein ratio.

Conditions

Interventions

OTHER

D2i2

Oleocanthal provided in a 2:1 ratio compared to oleacein

OTHER

D2i0.5

Oleocanthal provided in a 1:2 ratio compared to oleacein

OTHER

D2i0

No oleocanthal and no oleacein

DRUG

Ibuprofen

400 mg of Ibuprofen

Sponsors & Collaborators

  • USDA, Western Human Nutrition Research Center

    collaborator FED

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Roberta R Holt, PhD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-09-30
Completion
2015-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02902913 on ClinicalTrials.gov